What a slanted description designed to make it seem like Newsom is an elitist ...

"I'll say it right now ... the mRNA vaccines these are the safest and most effective vaccines in history."

Nice to have it on record you're simply blathering bullshit in order to sound smart.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777997/

2.1. Measles, Mumps, Rubella
One of the most common live attenuated vaccines in use today is the MMR vaccine. Although originally designed as three separate vaccines, attenuated strains of measles, mumps, and rubella were successfully formulated into a single combination vaccine in the US in 1971 (Strebel et al. 2013) and it continues to be used to provide protective immunity against pathogens responsible for what were once considered common childhood diseases. Similar to smallpox vaccination, they were developed against viruses that are antigenically stable and have only a single serotype. Even when combined with live, attenuated VZV to provide a quadrivalent vaccine, seroconversion rates remain high (measles; 97.1%, mumps; 96.0%, rubella; 98.8% and varicella; 93.5%, respectively) (Lieberman et al. 2006). Other vaccines against antigenically variable viruses (e.g., influenza) or pathogens with multiple serotypes (e.g., HPV) indicate that as vaccine technologies have improved and evolved, there are opportunities to combat more complicated and challenging pathogens through effective immunization programs. Although nearly all vaccines require at least one booster dose in order to maintain long-term protective immunity (Slifka and Amanna 2014), many of our most successful vaccines have achieved the appropriate balance of both safety and efficacy.

3.1. Hepatitis A
Infection with HAV was once a leading cause of viral hepatitis in the US, with 20,000–60,000 cases reported annually and fatality rates as high as 1.8% in adults >50 years of age (Centers for Disease Control and Prevention 2015c). Vaccine development against HAV benefited from several key factors including early studies demonstrating the efficacy of passive immunotherapy (Gellis et al. 1945; Havens and Paul 1945; Stokes and Neefe 1945; Hsia et al. 1954), the discovery of cell culture conditions for the propagation of HAV (Provost and Hilleman 1979), and passive and active immunization studies in appropriate animal models including chimpanzees and marmosets (Purcell et al. 1992; Provost et al. 1986). These critical elements supported the eventual development and licensure of two inactivated whole-virion, alum-adjuvanted vaccines (Havrix® and Vaqta®) in the US and since their implementation in the 1990s, the rates of disease have declined by >90% (Centers for Disease Control and Prevention 2015c). Efficacy for both vaccines is high, with estimates ranging from 94–100% (Werzberger et al. 1992; Innis et al. 1994). HAV-specific antibodies have been identified as the key correlate of protective immunity following vaccination, and although an absolute lower limit has not been defined, titers >10–20 mIU/mL are generally considered protective (Centers for Disease Control and Prevention 1996).